GIOTRIF®
First choice in first line EGFR M+

Proven efficacy in 3 large randomised trials of 1st line EGFR M+ NSCLC

Learn more

Indications & Usage

GIOTRIF® (afatinib) is approved in the European Union and other countries for the treatment of patients with distinct types of metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) mutations. For more information please see the EU Summary of Product Characteristics (SmPC).

COUNTRIES WHERE GIOTRIF® IS APPROVED

REFERENCES

  1. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
  2. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  3. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
  4. Park K et al. Abstract LBA2 and oral presentation. European Society for Medical Oncology (ESMO) ASIA, Singapore, 20th December 2015.